Novartis Highlights Advances For Breast Cancer, Hematological Diseases Patients NASDAQ The company noted that the CTRC-AACR San Antonio Breast Cancer Symposium, held from December 6-10, will feature data presentations from Phase III studies of Afinitor (everolimus) tablets for investigational uses and Zometa 4mg/5mL Injection, ... Novartis highlights advances for patients with breast cancer and hematological ... |
